{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:34:37Z","timestamp":1789544077159,"version":"build-2803163510"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The increasing incidence of drug-resistant <jats:italic toggle=\"yes\">Candida<\/jats:italic> brings a new challenge to the treatment of invasive candidiasis. Although cross-resistance among azoles and echinocandins was generally uncommon, reports of multidrug-resistant (MDR) <jats:italic toggle=\"yes\">Candida<\/jats:italic> markedly increased in the last decade. The purpose of this review is to understand mechanisms and risk factors for resistance and how to tackle antifungal resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The paper describes the action of the three main classes of antifungals - azoles, echinocandins and polyenes \u2013 and Candida's mechanisms of resistance. The current evolution from cross-resistance to multiresistance among Candida explains the modern glossary \u2212 multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) \u2013 imported from bacteria. MDR Candida most commonly involves acquired resistance in species with intrinsic resistance, therefore it mostly involves <jats:italic toggle=\"yes\">C. glabrata, C. parapsilosis, C. krusei, C guilliermondii<\/jats:italic> or <jats:italic toggle=\"yes\">C. auris<\/jats:italic>, which is intrinsically multidrug resistant. Finally, strategies to tackle antifungal resistance became clearer, ideally implemented through antifungal stewardship.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Avoiding antifungal's overuse and selecting the best drug, dose and duration, when they are needed, is fundamental. Knowledge of risk factors for resistance, microbiological diagnosis to the species, use of susceptibility test supported by antifungal stewardship programs help attaining effective therapy and sustaining the effectiveness of the current antifungal armamentarium.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcc.0000000000001077","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T03:18:25Z","timestamp":1693279105000},"page":"457-462","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of invasive candidiasis in the era of Candida resistance"],"prefix":"10.1097","volume":"29","author":[{"given":"Jos\u00e9-Artur","family":"Paiva","sequence":"first","affiliation":[{"name":"Intensive Care Medicine Department, Centro Hospitalar Universit\u00e1rio S. Jo\u00e3o, Porto, Portugal"},{"name":"Department of Medicine, Faculty of Medicine of University of Porto, Porto, Portugal"},{"name":"Grupo de Infe\u00e7\u00e3o e Sepsis, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Pereira","sequence":"additional","affiliation":[{"name":"Intensive Care Medicine Department, Centro Hospitalar Universit\u00e1rio S. Jo\u00e3o, Porto, Portugal"},{"name":"Department of Medicine, Faculty of Medicine of University of Porto, Porto, Portugal"},{"name":"Grupo de Infe\u00e7\u00e3o e Sepsis, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.chest.2021.08.081","article-title":"Risk factors for invasive candida infection in critically ill patients: a systematic review and meta-analysis","volume":"161","author":"Thomas-R\u00fcddel","year":"2022","journal-title":"Chest"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.idc.2021.03.001","article-title":"Recent trends in the epidemiology of fungal infections","volume":"35","author":"Seagle","year":"2021","journal-title":"Infect Dis Clin N Am"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11908-022-00782-5","article-title":"Antifungal resistance and the role of new therapeutic agents","volume":"24","author":"Logan","year":"2022","journal-title":"Curr Infect Dis Rep"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/IDR.S118892","article-title":"Fluconazole resistance in Candida species: a current perspective","volume":"10","author":"Berkow","year":"2017","journal-title":"Infect Drug Resist"},{"key":"R6-20250729","first-page":"557","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nature Rev"},{"key":"R7-20250729","doi-asserted-by":"crossref","DOI":"10.1177\/11786337211026927","article-title":"Candida blood stream infections: changes in epidemiology and increase in drug resistance","volume":"14","author":"Kotey","year":"2021","journal-title":"Infect Dis (Auckl)"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"102237","DOI":"10.1016\/j.mib.2022.102237","article-title":"Antifungal drug-resistance mechanisms in Candida biofilms","volume":"71","author":"Kaur","year":"2023","journal-title":"Current Opinion in Microbiology"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.01128-10","article-title":"Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving patients","volume":"55","author":"Lortholary","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.00479-10","article-title":"Risk factors for fluconazole-resistant candidemia","volume":"54","author":"Garnacho-Montero","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of SENTRY antifungal surveillance program: results for Candida species from 1997\u20132016","volume":"15","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"ofac447","DOI":"10.1093\/ofid\/ofac447","article-title":"Creation and internal validation of a clinical predictive model for Fluconazole resistance in patients with Candida bloodstream Infection","volume":"9","author":"Rauseo","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12831","article-title":"Mechanisms of echinocandin antifungal drug resistance","volume":"1354","author":"Perlin","year":"2015","journal-title":"Ann N Y Acad Sci"},{"issue":"(Suppl 2)","key":"R15-20250729","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/myc.12330","article-title":"Antifungal drug resistance among Candida species: mechanisms and clinical impact","volume":"58","author":"Sanguinetti","year":"2015","journal-title":"Mycoses"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"ofv163","DOI":"10.1093\/ofid\/ofv163","article-title":"Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008\u20132014","volume":"2","author":"Vallabhaneni","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"(Suppl 3)","key":"R17-20250729","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1093\/infdis\/jix131","article-title":"Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Arendrup","year":"2017","journal-title":"J Infect Dis"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/jof4030105","article-title":"Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata","volume":"4","author":"Healey","year":"2018","journal-title":"J Fungi"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1038\/s41467-022-32249-5","article-title":"The importance of antimicrobial resistance in medical mycology","volume":"13","author":"Gow","year":"2022","journal-title":"Nat Commun"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"11128","DOI":"10.1038\/ncomms11128","article-title":"Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multidrug resistance","volume":"7","author":"Healey","year":"2016","journal-title":"Nat Commun"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"ofac605","DOI":"10.1093\/ofid\/ofac605","article-title":"Global emergence of resistance to Fluconazole and Voriconazole in Candida parapsilosis in tertiary hospitals in Spain during the COVID-19 pandemic","volume":"9","author":"Trevijano-Contador","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhin.2016.08.004","article-title":"Multidrug-resistant Candida auris: \u2018new kid on the block\u2019 in hospital-associated infections?","volume":"94","author":"Chowdhary","year":"2016","journal-title":"J Hosp Infect"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.mycmed.2022.101248","article-title":"Overview about Candida auris: what's up 12\u200ayears after its first description?","volume":"32","author":"Desoubeaux","year":"2022","journal-title":"J Mycol Med"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"102208","DOI":"10.1016\/j.mib.2022.102208","article-title":"The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida auris","volume":"70","author":"Rybak","year":"2022","journal-title":"Curr Opin Microbiol"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40121-022-00625-9","article-title":"Candida auris Candidemia in critically ill, colonized patients: cumulative incidence and risk factors","volume":"11","author":"Briano","year":"2022","journal-title":"Infect Dis Ther"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12941-019-0323-z","article-title":"A systematic review of the impact of antifungal stewardship interventions in the United States","volume":"18","author":"Hart","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"R31-20250729","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2016.07.025","article-title":"Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia","volume":"22","author":"Imbert","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin Ther"},{"key":"R33-20250729","first-page":"3488","article-title":"Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital","volume":"73","author":"Rautemaa-Richardson","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1128\/AAC.01750-10","article-title":"Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans","volume":"55","author":"Wiederhold","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/jof7090731","article-title":"Role of antifungal combinations in difficult to treat Candida infections","volume":"7","author":"Vitale","year":"2021","journal-title":"J Fungi"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"e1006290","DOI":"10.1371\/journal.ppat.1006290","article-title":"Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally","volume":"13","author":"Chowdhary","year":"2017","journal-title":"PLoS Pathog"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S2666-5247(20)30194-4","article-title":"Micafungin and amphotericin B synergy against Candida auris","volume":"1","author":"Jaggavarapu","year":"2020","journal-title":"Lancet Microb"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"e02195","DOI":"10.1128\/AAC.02195-19","article-title":"In vitro evaluation of antifungal drug combinations against multidrug-resistant Candida auris isolates from New York outbreak","volume":"64","author":"O\u2019Brien","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/antibiotics9090558","article-title":"Characteristics and management of candidaemia episodes in an established Candida auris outbreak","volume":"9","author":"Bayona","year":"2020","journal-title":"Antibiotics (Basal)"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.3390\/molecules25215114","article-title":"Synergistic antifungal activity of chitosan with fluconazole against Candida albicans, Candida tropicalis and fluconazole-resistant strains","volume":"25","author":"Lo","year":"2020","journal-title":"Molecules"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"e0072522","DOI":"10.1128\/aac.00725-22","volume":"66","author":"An","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R43-20250729","doi-asserted-by":"crossref","first-page":"e02614","DOI":"10.1128\/AAC.02614-17","article-title":"Overcoming the resistance hurdle: pharmacokinetic-pharmacodynamic target attainment analyses for Rezafungin (CD101) against Candia albicans and Candida glabrata","volume":"62","author":"Bader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R44-20250729","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/jac\/dkz280","article-title":"In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris","volume":"74","author":"Rudramurthy","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R45-20250729","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-021-00376-x","article-title":"Pharmacokinetics and pharmacodynamics of ibrexafungerp","volume":"22","author":"McCarthy","year":"2022","journal-title":"Drugs R D"},{"key":"R46-20250729","doi-asserted-by":"crossref","first-page":"140.e1","DOI":"10.1016\/j.cmi.2021.09.030","article-title":"In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method","volume":"28","author":"Mesquida","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"R47-20250729","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01692-19","article-title":"In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations","volume":"63","author":"Nunnally","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R48-20250729","doi-asserted-by":"crossref","first-page":"e02694","DOI":"10.1128\/AAC.02694-20","article-title":"Ibrexafungerp demonstrates in vitro activity against fuconazole-resistant Candida auris and in vivo efcacy with delayed initiation of therapy in an experimental model of invasive candidiasis","volume":"65","author":"Wiederhold","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R49-20250729","doi-asserted-by":"crossref","first-page":"e01124","DOI":"10.1128\/AAC.01124-20","article-title":"In vitro activity of manogepix against multidrug-resistant and panresistant Candida auris from the New York outbreak","volume":"64","author":"Zhu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R50-20250729","doi-asserted-by":"crossref","first-page":"103953","DOI":"10.1016\/j.isci.2022.103953","article-title":"The role of Candida albicans stress response pathways in antifungal tolerance and resistance","volume":"25","author":"Iyer","year":"2022","journal-title":"iScience"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:09:24Z","timestamp":1753819764000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000001077","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"value":"1070-5295","type":"print"},{"value":"1531-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}